


AMENDMENTS TO THE CLAIMS

Claim 1 (previously amended)

Ethyl (2S)-2-(naphthalene-1-sulfonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionate hemifumarate of the formula




Claim 2 (previously amended)

A pharmaceutical composition for treating bone diseases comprising an amount of compound of claim 1 sufficient to treat bone diseases and a pharmaceutically acceptable carrier.

Claim 3 (currently amended)


A process for the preparation of ethyl (2S)-2-(naphthalene-1-sulfonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionate ~~or propionate~~ propionate or a salt thereof, comprising reacting 4-(2-(1,4,5,6-

tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoic acid or a derivative of the formula



II

wherein X is hydroxy or a leaving group, with ethyl (2S)-3-amino-2-(naphthalene-1-sulfonylamino)propionate of the formula



III


or a an acid addition salt or salts of any one or ~~both~~ both of the said compounds.

Claim 4 (previously amended)

The process of claim 3 wherein X is chlorine.

Claim 5 (previously amended)

The process of claim 3 wherein the reaction product of the compounds of the formulae II and III is reacted with an acid to form the acid addition salt of the compound of the formula



IV

Claims 6 to 10 (currently cancelled)

Claim 11 (previously added)

A method of treating bone diseases in humans comprising administering to humans in need thereof an amount of the compound of claim 1 sufficient to treat bone diseases.